5 Key Takeaways
-
1
New drug discovery technologies are advancing therapies across various modalities, including molecular glues and protein degraders.
-
2
Cell therapies are expanding their applications to solid tumors and autoimmune diseases, showcasing significant potential.
-
3
Challenges remain in demonstrating value to investors in a capital-constrained environment within the industry.
-
4
The coexistence of different therapeutic modalities as part of a mixed ecosystem is a critical consideration for the field.
-
5
The Power List 2026 features 60 individuals recognized for their contributions, with 20 in each category: Small Molecules, Biopharma, and Advanced Medicines.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
